editorijrpas@gmail.com

International Journal of Research in Pharmacy and Allied Science

ISSN: 2583-6544 | Issues per year: Monthly | Indexed In: Google Scholar, CORE, ScienceOpen, Researchgate

ISSN:2583-6544

Abstract View

Pharmaceutical Marketing Role to Adapt Drug Promotional Practices at the duration times of Pandemic Covid-19

Author(s): Ms. Rupali Singh1*¹, Mr. Victor Dey2²

Email(s): ¹priyupatil9322@gmail.com

Address:

1. P.G. Scholar of SSPU, Department of Pharmacology, 2Shri Shankaracharya Professional University (SSPU), Junwani, Bhilai-490020 (C.G.), India. 2. P.G. Scholar of SSPU, Department of Pharmaceutical Chemistry, Shri Shankaracharya Professional University (SSPU), Junwani, Bhilai-490020 (C.G.), India.

Published In: Volume - 4, Issue - 4, Year - 2025

DOI: https://doi.org/10.71431/IJRPAS.2025.4418

View HTML

View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Pharmaceutical marketing is an essential societal activity that ensures the availability of medicines at the right time and place. Pharmaceutical marketers providing timely needed information to perform after-sales service in the distribution chain and organize medical conferences and seminars. Thus, their therapies and products updating to ensuring availability and usage of medications are catalyzed by pharmaceutical marketers. This also ensures access to medicines in society. Medical representatives (MRs) are critical elements providing inform and persuade adoption of various products for patient welfare. To complement and supplement the ground-level pharmaceutical marketing activity, a host of digital marketing initiatives is also accoutering the pharmaceutical marketing process. During pandemics like COVID-19 infection, face-to-face pharmaceutical marketing approach is thrown out of gear and digital marketing has gained increased adoption. This article reviews the adaptive responsive ways of pharmaceutical marketers during COVID-19 duration period of time.

Keywords:

Cite this article:
Ms. Rupali Singh, Mr. Victor Dey. Pharmaceutical Marketing Role to Adapt Drug Promotional Practices at the duration times of Pandemic Covid-19. IJRPAS, April 2025; 4 (4): 162-178.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4418

1. Levy R. The role and value of pharmaceutical marketing. Arch Fam Med. 1994;3:327-332.
2.      Patel AJ, Dumatar CB. Influence of medical representative on knowledge, attitude and practice of medical practitioners in private setup. IJSR. 2015;4(10):442-446.
3.      Charen MM, Lenderfeld S, Muray TH. Doctors, drug companies and gifts. JAMA. 1989; 262: 3448-3451.
4.      Peterson AF. The professional service pharmacist. J Am Pharm Assoc. 1949;212.
5.      Ankush C, Virendra SL, et al. A survey on doctor’s expectation from medical representatives in Karnataka State. Int J Cur Res Rev. 2015;7(8):75-82.
6.      Guo Y-R, Cao Q-D, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - An update on the status. Mil Med Res. 2020;7(11):1-10.
7.      Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: A systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):1-14.
8.      Gaedeke RM, Tootelian DH, Sanders EE. Value of services provided by pharmaceutical companies: Perceptions of physicians and pharmaceutical sales representatives. Haworth Press, Inc. 1999;17(1):23-31.
9.      Barton L. Ethics, profits and patients: When pharmaceutical companies sponsor medical meetings. J Hosp Mark. 1993;8(1):71.
10.  Lotfi T, Morsi RZ, et al. Validity of tools used for surveying physicians about their interactions with pharmaceutical companies: A systematic review. BMC Res Notes. 2015;8(720):1-8.
11.  Lotfi T, Morsi RZ, et al. Knowledge, beliefs and attitudes of physicians in low and middle-income countries regarding interacting with pharmaceutical companies: A systematic review. BMC Health Serv Res. 2016;16(57):1-11.
12.  Brax H, Fadlallah R, et al. Association between physicians' interaction with pharmaceutical companies and their clinical practices: A systematic review and meta-analysis. PLOS ONE. 2017;12(4):1-28.
13.  Khazzaka M. Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: Ethics, gifts and samples. BMC Health Serv Res. 2019;19(80):1-11.
14.  Spiller LD, Jr., Wymer WW. Physicians' perceptions and uses of commercial drug information sources: An examination of pharmaceutical marketing to physicians. Haworth Press, Inc. 2001;19(1):91-105.
15.  Anadaleeb SS, Tallman RF. Relationships of physicians with pharmaceutical sales representatives and pharmaceutical companies: An exploratory study. Haworth Press, Inc. 1996;13(4):79-89.
16.  Fickweiler F, Fickweiler W, Urbach E. Interactions between physicians and the pharmaceutical industry generally and sales representatives specifically and their association with physicians' attitudes and prescribing habits: A systematic review. BMJ Open. 2017;7:1-12.
17.  Pokharel PR. Promotional tools effect on pharmaceuticals marketing. Am J Med. 2017;130(6):79-84.
18.  Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:1-7.
19.  Ksiazek TG, Erdman D, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003; 348: 1953-1966.
20.  Li Q, Guan X, et al. Early transmission dynamics in Wuhan, China of novel coronavirus infected pneumonia. N Engl J Med. 2020; 382: 1199-1207.
21.  Koo J, Cook A, et al. Interventions to mitigate early spread of SARS-CoV-2 in Singapore: A modelling study. Lancet Infect Dis. 2020;20(6):1-11.
22.  Hagen T. COVID-19 will test digital marketing of pharmaceuticals. Center for Biosimilars. AJMC; 2020. Available from: https://www.centerforbiosimilars.com/news/covid-19-will-test-digital-marketing-of
23.  Brown J L. Physician exposure to direct-to-consumer pharmaceutical marketing: Potential for creating prescribing bias. Am J Med. 2017;130(6):e247-e248.
24.  Bhole L, Verma S. Digital marketing: A road ahead to pharmaceutical selling. IOSR J Bus Manag. 2018:61-5.
25.  Wagner K C, Cimpl B, Byrd G D. Evaluating the effectiveness of clinical medical librarian programs: A systematic review of the literature. J Med Libr Assoc. 2004;92(1):14-33.
26.  Cimpl K. Clinical medical librarianship: A review of the literature. Bull Med Libr Assoc. 1974;62(4):354-8.
27.  Online pharmacies: A boon or bane? Indian J Pharmacol. 2016;48(6):615-6.
28.  Perrir A, Bonnin A, et al. The C-terminal domain of the MERS coronavirus M protein contains a trans Golgi network localization signal. J Biol Chem. 2019;294(39):14406-14421.
29.  Wilson C E. The effect of medium on loss of information. Journalism Q. 1974;651:111-5.
30.  Young M E, Norman G R, Humphreys K R. Medicine in the popular press: The influence of the media on perceptions of disease. PLoS ONE. 2008;3(10):1-7.
31.  Bulik B S. Marketing grounded by the pandemic, pharma reps turn to digital tools to reach docs. Fierce Pharma. Available from: https://www.fiercepharma.com/marketing/pharma-sales-reps-stay-home-minimize-face-time-physicians-as-covid-19-spread-continues.

Related Images:

Recent Images

RPHPLC Method for Concurrent Determination of Haloperidol and Trihexyphenidyl in API and Combined Tablet Formulations

A review on HPLC Methods for Estimation of Travoprost in Combined and Single Pharmaceutical formulation and Bulk

To Study number and types of refund Medicines from different Wards of Hospital to the In-Patient Pharmacies

A Novel RP-HPLC Analytical Method Development and Validation of Berberine In Bulk and Polyherbal Formulation

Formulation and Evaluation of A Polyherbal Cough Syrup with Potential Anti-Obesity Effects

Formulation and evaluation of Herbal Face Cream

Formulation and In-vitro Evaluation of Cold Cream

Design and Optimization of Extended-Release Mini-Tablets of Metoprolol Succinate Using Okra Stalk Powder and HPMC K100 M as Release Modifiers

Comprehensive review on Alfuzosin quantification: Analytical techniques and the evolution of AQbD in method development